Sign In

Login

Password

Forgot Password ? Sign Up

HER2/neu (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "HER2/neu" in German language version.

refsWebsite
Global rank German rank
6doi.org
2nd place
3rd place
5nih.gov
4th place
7th place
4zdb-katalog.de
123rd place
6th place
1genenames.org
low place
low place
1lww.com
2,769th place
2,484th place
1sciencedirect.com
149th place
298th place
1aerzteblatt.de
3,043rd place
200th place
1web.archive.org
1st place
1st place
1redirecter.toolforge.org
33rd place
2nd place
1europa.eu
68th place
29th place

aerzteblatt.de

doi.org

  • Y. Bang, H. Chung, J. Xu, F. Lordick, A. Sawaki: Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. In: Journal of Clinical Oncology. Band 27, 15_suppl, 20. Mai 2009, ISSN 0732-183X, S. 4556–4556, doi:10.1200/jco.2009.27.15_suppl.4556 (englisch).
  • Luca Albarello, Lorenza Pecciarini, Claudio Doglioni: HER2 Testing in Gastric Cancer. In: Advances in Anatomic Pathology. Band 18, Nr. 1, Januar 2011, ISSN 1072-4109, S. 53–59, doi:10.1097/PAP.0b013e3182026d72 (englisch, lww.com [abgerufen am 20. Juni 2020]).
  • Hee Eun Lee, Kyoung Un Park, Seol Bong Yoo, Soo Kyung Nam, Do Joong Park: Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. In: European Journal of Cancer. Band 49, Nr. 6, 1. April 2013, ISSN 0959-8049, S. 1448–1457, doi:10.1016/j.ejca.2012.10.018 (englisch, sciencedirect.com [abgerufen am 20. Juni 2020]).
  • Branka Petricevic, Johannes Laengle, Josef Singer, Monika Sachet, Judit Fazekas, Guenther Steger, Rupert Bartsch, Erika Jensen-Jarolim, Michael Bergmann: Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. In: Journal of Translational Medicine. Band 11, Nr. 1, Dezember 2013, ISSN 1479-5876, S. 307, doi:10.1186/1479-5876-11-307, PMID 24330813, PMC 4029549 (freier Volltext) – (englisch).
  • F. Penault-Llorca, M. Bilous, M. Dowsett et al.: Emerging technologies for assessing HER2 amplification. In: Am. J. Clin. Pathol. Band 132, Nr. 4, Oktober 2009, S. 539–548, doi:10.1309/AJCPV2I0HGPMGBSQ, PMID 19762531 (englisch).
  • S. Stortecky, T. M. Suter: Insights into cardiovascular side-effects of modern anticancer therapeutics. In: Curr Opin Oncol. Band 22, Nr. 4, Juli 2010, S. 312–307, doi:10.1097/CCO.0b013e32833ab6f1, PMID 20535072 (englisch).

europa.eu

ema.europa.eu

genenames.org

lww.com

journals.lww.com

  • Luca Albarello, Lorenza Pecciarini, Claudio Doglioni: HER2 Testing in Gastric Cancer. In: Advances in Anatomic Pathology. Band 18, Nr. 1, Januar 2011, ISSN 1072-4109, S. 53–59, doi:10.1097/PAP.0b013e3182026d72 (englisch, lww.com [abgerufen am 20. Juni 2020]).

nih.gov

ncbi.nlm.nih.gov

  • Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51. PMID 17611206
  • Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001;3(6):385-9. PMID 11737890, PMC 138705 (freier Volltext)
  • Branka Petricevic, Johannes Laengle, Josef Singer, Monika Sachet, Judit Fazekas, Guenther Steger, Rupert Bartsch, Erika Jensen-Jarolim, Michael Bergmann: Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. In: Journal of Translational Medicine. Band 11, Nr. 1, Dezember 2013, ISSN 1479-5876, S. 307, doi:10.1186/1479-5876-11-307, PMID 24330813, PMC 4029549 (freier Volltext) – (englisch).
  • F. Penault-Llorca, M. Bilous, M. Dowsett et al.: Emerging technologies for assessing HER2 amplification. In: Am. J. Clin. Pathol. Band 132, Nr. 4, Oktober 2009, S. 539–548, doi:10.1309/AJCPV2I0HGPMGBSQ, PMID 19762531 (englisch).
  • S. Stortecky, T. M. Suter: Insights into cardiovascular side-effects of modern anticancer therapeutics. In: Curr Opin Oncol. Band 22, Nr. 4, Juli 2010, S. 312–307, doi:10.1097/CCO.0b013e32833ab6f1, PMID 20535072 (englisch).

redirecter.toolforge.org

  • Data From Omnitarg Clinical Program Presented at American Society of Clinical Oncology Meeting. Genentech, archiviert vom Original am 13. Juli 2014; abgerufen am 27. Januar 2023 (english).

sciencedirect.com

  • Hee Eun Lee, Kyoung Un Park, Seol Bong Yoo, Soo Kyung Nam, Do Joong Park: Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. In: European Journal of Cancer. Band 49, Nr. 6, 1. April 2013, ISSN 0959-8049, S. 1448–1457, doi:10.1016/j.ejca.2012.10.018 (englisch, sciencedirect.com [abgerufen am 20. Juni 2020]).

web.archive.org

  • Data From Omnitarg Clinical Program Presented at American Society of Clinical Oncology Meeting. Genentech, archiviert vom Original am 13. Juli 2014; abgerufen am 27. Januar 2023 (english).

zdb-katalog.de

  • Y. Bang, H. Chung, J. Xu, F. Lordick, A. Sawaki: Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. In: Journal of Clinical Oncology. Band 27, 15_suppl, 20. Mai 2009, ISSN 0732-183X, S. 4556–4556, doi:10.1200/jco.2009.27.15_suppl.4556 (englisch).
  • Luca Albarello, Lorenza Pecciarini, Claudio Doglioni: HER2 Testing in Gastric Cancer. In: Advances in Anatomic Pathology. Band 18, Nr. 1, Januar 2011, ISSN 1072-4109, S. 53–59, doi:10.1097/PAP.0b013e3182026d72 (englisch, lww.com [abgerufen am 20. Juni 2020]).
  • Hee Eun Lee, Kyoung Un Park, Seol Bong Yoo, Soo Kyung Nam, Do Joong Park: Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. In: European Journal of Cancer. Band 49, Nr. 6, 1. April 2013, ISSN 0959-8049, S. 1448–1457, doi:10.1016/j.ejca.2012.10.018 (englisch, sciencedirect.com [abgerufen am 20. Juni 2020]).
  • Branka Petricevic, Johannes Laengle, Josef Singer, Monika Sachet, Judit Fazekas, Guenther Steger, Rupert Bartsch, Erika Jensen-Jarolim, Michael Bergmann: Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. In: Journal of Translational Medicine. Band 11, Nr. 1, Dezember 2013, ISSN 1479-5876, S. 307, doi:10.1186/1479-5876-11-307, PMID 24330813, PMC 4029549 (freier Volltext) – (englisch).